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Granule cell dispersion (GCD) is a common pathological feature observed in the hippocampus 37 
of patients with Mesial Temporal Lobe Epilepsy (MTLE). Pathomechanisms underlying GCD 38 
remain to be elucidated, but one hypothesis proposes aberrant reactivation of 39 
neurodevelopmental migratory pathways, possibly triggered by febrile seizures. This study 40 
aims to compare the proteomes of basal and dispersed granule cells in the hippocampus of eight 41 
MTLE patients with GCD to identify proteins that may mediate GCD in MTLE.  42 
 43 
Quantitative proteomics identified 1882 proteins, of which 29% were found in basal granule 44 
cells only, 17% in dispersed only and 54% in both samples. Bioinformatics analyses revealed 45 
upregulated proteins in dispersed samples were involved in developmental cellular migratory 46 
processes, including cytoskeletal remodelling, axon guidance and signalling by Ras 47 
homologous (Rho) family of GTPases (P<0.01). The expression of two Rho GTPases, RhoA 48 
and Rac1, was subsequently explored in immunohistochemical and in situ hybridisation studies 49 
involving eighteen MTLE cases with or without GCD, and three normal post mortem cases. In 50 
cases with GCD, most dispersed granule cells in the outer-granular and molecular layers have 51 
an elongated soma and bipolar processes, with intense RhoA immunolabelling at opposite poles 52 
of the cell soma, while most granule cells in the basal granule cell layer were devoid of RhoA. 53 
A higher density and percentage of cells expressing RhoA was observed in cases with GCD 54 
than without GCD (P<0.004). In GCD cases, the density and percentage of cells expressing 55 
RhoA was significantly higher in the inner molecular layer than granule cell layer (P<0.026), 56 
supporting proteomic findings. In situ hybridisation studies using probes against RHOA and 57 
RAC1 mRNAs revealed fine peri- and nuclear puncta in granule cells of all cases. The density 58 
of cells expressing RHOA mRNAs were significantly higher in the inner molecular layer of 59 
cases with GCD than without GCD(P=0.05). In summary, our study has found limited evidence 60 
for ongoing adult neurogenesis in the hippocampus of patients with MTLE, but evidence of 61 
differential dysmaturation between dispersed and basal granule cells has been demonstrated, 62 
and elevated expression of Rho GTPases in dispersed granule cells may contribute to the 63 




Temporal lobe epilepsy is the most common form of pharmacoresistant epilepsy in adults 66 
(Engel, 1998). Up to 80% of patients with mesial form of temporal lobe epilepsy (MTLE) have 67 
structural abnormalities in the hippocampus (de Tisi et al., 2011; Blumcke et al., 2017). Over 68 
60% of patients with MTLE and hippocampal pathologies remained seizure-free for at least a 69 
year after surgical resection of the hippocampus as treatment for their epilepsy (de Tisi et al., 70 
2011; Engel et al., 2012; Blumcke et al., 2017), suggesting that the hippocampus is the primary 71 
site for epileptogenesis.  72 
 73 
Hippocampal Sclerosis ILAE Type 1 (HS Type 1) is the most common pathology observed in 74 
patients with pharmacoresistant MTLE, and it is primarily characterised by segmental loss of 75 
pyramidal neurons in cornu Ammonis subfields CA1, 3, and 4 (Blumcke et al., 2017). Over 76 
half of the MTLE patients with HS Type 1 also have abnormalities affecting dentate granule 77 
cells (DGCs) including granule cell dispersion (GCD) and mossy fibre sprouting (Wieser, 78 
2004; Blümcke et al., 2009; Thom et al., 2010; Da Costa Neves et al., 2013). In the normal 79 
human hippocampus, DGCs are organised into a compact layer of up to ten cells thick or 80 
≤120µm (Houser, 1990; Wieser, 2004). In GCD, ectopic DGCs in clusters or rows disperse to 81 
the inner and outer molecular layers of the sclerotic hippocampus, widening the granule cell 82 
layer to up to 400 µm in thickness (Blümcke et al., 2009). The presence, severity and extent of 83 
GCD along the hippocampal body is highly variable amongst patients with MTLE (Thom et 84 
al., 2010; Blumcke et al., 2013) and there is no confirmed grading scheme for GCD in MTLE. 85 
The exact cause of GCD in human MTLE is unknown; however, animal models of MTLE with 86 
or without hippocampal sclerosis have shown that seizures can displace the migration of newly-87 
generated (Parent et al., 2006; Hester et al., 2013) and mature DGCs to CA4 and molecular 88 
layer (Murphy et al., 2011; Ryuta et al., 2012; Chai et al., 2014). Reelin is an extracellular 89 
matrix glycoprotein secreted by Cajal-Retzius cells during neurodevelopment to regulate the 90 
correct layering of migrating cells (Frotscher, 1998). Low levels of reelin transcript and protein 91 
have been reported in the hippocampus of patients with MTLE (Haas et al., 2002; Haas et al., 92 
2010) and animal models of MTLE (Heinrich et al., 2006), possibly as a consequence of 93 
elevated methylation at the promotor region of RELN (Kobow et al., 2009) or loss of reelin-94 
synthesising neurons in hippocampus (Haas et al., 2002; Orcinha et al., 2016). The loss of 95 
reelin in MTLE is believed to lead to ‘over-running’ of DGCs into the molecular layer. Past 96 
studies have shown that pharmacological inhibition of mammalian target of rapamycin 97 
(mTOR) pathway can prevent the development of the mossy fibre sprouting (Buckmaster et 98 
al., 2009) and reduce the severity of GCD in animal models of MTLE (Lee et al., 2018), 99 
suggesting that the mTOR pathway may have a role in the pathomechanisms of these 100 
abnormalities. In patients with MTLE, most astroglial cells strongly expressed markers of 101 
mTOR signalling activation such as phospho-S6 ribosomal protein in the sclerotic 102 
hippocampus, whereas DGCs showed minimal immunohistochemical evidence of mTOR 103 
activation (Sha et al., 2012; Sosunov et al., 2012; Liu et al., 2014). Clinicopathological studies 104 
reported that the presence of GCD in patients with MTLE was associated with a history of early 105 
onset of epilepsy and febrile seizures (<4years) and longer duration of epilepsy (Lurton et al., 106 
1998; Blümcke et al., 2009) suggesting that GCD may be a consequence of seizures or brain 107 
trauma acquired during the first decade of life where dentate neurogenesis is still active. 108 
Although it is unclear whether the presence of GCD is associated with positive surgical 109 
outcomes for patients with pharmacoresistant MTLE based on existing literature (Blümcke et 110 
al., 2009; Thom et al., 2010; Da Costa Neves et al., 2013), there is supportive evidence from 111 
animal studies to show that ectopic DGCs increase hippocampal excitability by having a lower 112 
activation threshold, forming excess dendritic axonal connections and receiving more 113 
excitatory and fewer inhibitory synaptic inputs than normal cells (Murphy, Danzer, 2011)(Zhan 114 
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et al., 2010)(Althaus et al., 2019). In patients with MTLE, GCD is often observed in 115 
conjunction with mossy fibre sprouting, where mossy fibres of DGCs form excitatory synaptic 116 
contact with apical dendrites and spines of neighbouring DGCs in the molecular layer (Sutula 117 
et al., 1989; Cavazos et al., 2003), thus potentially creating an internal, pro-epileptogenic 118 
circuit.  119 
 120 
DGCs are functionally important for cognition and memory since they filter the main inputs 121 
into the hippocampus, and propagate signals by innervating pyramidal neurons in CA3 and 122 
CA1. Electrophysiological in vivo animal studies have demonstrated that DGCs normally have 123 
low-excitability, and only a small, spatially-defined population of DGCs would fire to allow 124 
the execution of fine and spatially-complex activities such as pattern separation, novelty 125 
detection and spatial discrimination (Kahn et al., 2019). Stimulated DGCs release vesicles 126 
containing glutamate to activate population firing of interconnected CA3 pyramidal cells 127 
(Miles et al., 1983; Scharfman et al., 2014).  Consequently, many stimulated DGCs would 128 
enhance hippocampal excitability, thus increasing the chances of seizures (Overstreet-Wadiche 129 
et al., 2006; Hester, Danzer, 2013), and reducing the ability to perform fine, spatial 130 
discrimination tasks (Kahn et al., 2019). Silencing DGCs using ontogenetic manipulation can 131 
reduce seizure frequency and reverse cognitive impairments in animal models of MTLE 132 
(Krook-Magnuson et al., 2015). 133 
 134 
In view of the important role DGCs play in cognition and promoting epileptogenesis, it is 135 
important to understand mechanisms and substrates driving abnormal displacement of DGCs 136 
in patients with MTLE. The proteome of the human hippocampus has been studied in normal 137 
(Edgar et al., 1999a; Föcking et al., 2012; Koopmans et al., 2018), and diseased post mortem 138 
human brains, including in the context of schizophrenia (Edgar et al., 1999b), Alzheimer’s 139 
disease (Edgar et al., 1999b; Sultana et al., 2007; Begcevic et al., 2013; Hondius et al., 2016), 140 
and non-neural malignancies (Yang et al., 2004a). In epilepsy, the proteomes of surgically-141 
resected hippocampi from patients with refractory TLE (Czech et al., 2004; Yang et al., 2004b; 142 
Yang et al., 2006; Persike et al., 2012; Mériaux et al., 2014; Persike et al., 2018) or temporal 143 
cortex (Eun et al., 2004; He et al., 2006; Keren-Aviram et al., 2018) have been studied . Most 144 
of these past studies investigated the whole hippocampus rather than specific hippocampal 145 
subregions, and information about structural hippocampal pathology was not disclosed in three 146 
studies (Czech et al., 2004; Persike et al., 2012; Persike et al., 2018). None of the previous 147 
human proteomic studies discussed GCD in their samples. We aimed to investigate the 148 
proteomes of DGCs located in the basal and dispersed regions of the granule and molecular 149 
layers of patients with HS Type 1 and GCD, and to identify the molecular substrates that 150 
mediate GCD. Ectopic DGCs are potential substrates for recurrent excitation, and they may be 151 
the key to understanding MTLE with hippocampal sclerosis and GCD, and its comorbidities 152 
including cognitive and memory impairments.  153 
 154 
Materials and methods 155 
 156 
Cases 157 
Patients with refractory MTLE who had undergone surgical resection of hippocampus as 158 
treatment for their epilepsy between 2005 and 2016 were identified from the records of UCL 159 
Epilepsy Society Brain and Tissue Bank (Table 1). All patients provided written informed 160 
consent for use of tissue in research studies in accordance with the Declaration of Helsinki, and 161 
the study has obtained ethical approval. Eight cases with age at surgery ranged from 20 to 60 162 
years were submitted to proteomic analysis. All cases had HS Type 1 with marked GCD 163 




At initial neuropathological assessment, two 5mm-thick blocks from each case were coronally 166 
sampled from the middle of the hippocampus (2 cm from anterior tip) to ensure that the dentate 167 
gyrus was presented for assessment and subsequent experiments. One block of the sampled 168 
hippocampus was snap-frozen in liquid nitrogen, stored in -70 freezers and later retrieved for 169 
proteomic studies, while the other block was fixed in 10% neutral-buffered formalin, processed 170 
and embedded in paraffin wax for histological staining and immunohistochemistry.  171 
 172 
Laser Capture Microdissection 173 
Fourteen sections of 14 µm thickness were sectioned from each frozen hippocampal sample, 174 
and sections were collected onto polyethylene terephthalate metal frame slides for laser capture 175 
microdissection (Leica, Milton Keynes, UK). Two additional sections were collected onto a 176 
microscopic slide (VWR International, UK) and stained briefly in 0.1% toluidine blue (pH 4.5) 177 
solution for five seconds to visualise the granule cell layer. Laser capture microdissection 178 
(LCM 700; Leica, Milton Keynes, UK) was then carried out along the entire length of the GCL 179 
of multiple sections per case to capture basal and dispersed DGCs (Figure 2A). Basal samples 180 
included DGCs in the granule cell layer closest to CA4, while the dispersed samples included 181 
ectopic DGCs in the outer-granular layer and inner and outer molecular layers. A total tissue 182 
area of 91 mm2 was dissected for each case, and submitted for proteomic analysis. 183 
 184 
Proteomic and bioinformatics analyses 185 
Samples were denatured using in-solution trypsin digestion and prepared for MSe label-free 186 
quantitative proteomics as described previously (Heywood et al., 2013; Manwaring et al., 2013; 187 
Liu et al., 2016). Data was processed using ProteinLynx GlobalServer version 2.5. Protein 188 
identifications were obtained by searching the UniProt reference human proteomes with the 189 
sequence of porcine trypsin (P00761) added. Protein identification from the low/high collision 190 
spectra for each sample was processed using a hierarchical approach where more than three 191 
fragment ions per peptide, seven fragment ions per protein, and more than two peptides per 192 
protein had to be matched. Peptide identification was accepted if they could be established at 193 
95% or greater probability. Statistical analyses of group means were performed using t-test in 194 
SPSS (v25; IBM, USA) to identify significantly differentially expressed proteins between 195 
dispersed and basal samples, or younger and older cohorts (P<0.05). Younger cohort consisted 196 
of four cases with an age at surgery ranging from 20 to 34 years, and the older cohort included 197 
four cases with an age at surgery ranging from 51 to 60 years. For volcano plots, fold change 198 
between groups was transformed using base 2 logarithmic transformation and plotted against 199 
negative logarithmic transformation of P-value. List of differentially expressed proteins in 200 
Basal, Dispersed, Younger and Older clusters included proteins found only in the respective 201 
samples, and proteins that were significantly different between comparison group (fold 202 
change>1.5, P<0.05). Enriched lists were analysed using bioinformatics resources, Database 203 
for Annotation, Visualisation and Integrated Discovery (DAVID; version 6.8; (Huang da et al., 204 
2009b, 2009a) and Enrichr (Chen et al., 2013; Kuleshov et al., 2016), to obtain information 205 
regarding biological, cellular and molecular functions of proteins. Interactions between 206 
proteins were investigated using STRING analysis (https://string-db.org/), and proteins in 207 
functional pathways were explored in established pathway databases, Kyoto Encyclopaedia of 208 
Genes and Genomes (KEGG), Reactome, and Wikipathways. P values and adjusted P values 209 
(corrected according to Bonferroni’s method and false discovery rate) were calculated by 210 
bioinformatics resources. For gene ontology annotation and enriched pathway analyses, 211 
stringency of the criteria was set to high, and P value cut-off was set at 0.01 and only pathways 212 
with four proteins of interests or more were presented. The dendrogram was constructed using 213 
Morpheus (Broad Institute; https://software.broadinstitute.org/morpheus) and included 214 
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hierarchical clustering based on Pearson correlation coefficient, and average linkage clustering 215 
(Meunier et al., 2007).  216 
 217 
Other clinical details, including patients’ epilepsy history and psychometry were also reviewed 218 
and analysed with proteomic data. Pre-operative MRI sequences, PET, EEG, video-telemetry, 219 
and psychometry had been carried out according to the epilepsy surgical protocols at the 220 
National Hospital of Neurology and Neurosurgery, and clinical findings were reviewed for 221 
each case. 222 
 223 
Immunohistochemistry 224 
Eighteen cases were included in RhoA, Rac1, and Cdc42 immunohistochemistry and/or in situ 225 
hybridisation studies. Cases included eight MTLE cases submitted for proteomics, an 226 
additional six surgical MTLE with hippocampal sclerosis and GCD, four surgical MTLE with 227 
hippocampal sclerosis but no GCD, and three postmortem healthy controls (Table 1).  228 
 229 
5µm-thick formalin-fixed, paraffin-embedded sections from selected cases were examined 230 
histologically with Haematoxylin and Eosin, and Luxol Fast Blue stains. Routine automated 231 
immunochemistry was performed using antibodies against neuronal nuclei (NeuN), glial 232 
fibrillary acidic protein (GFAP), non/phosphorylated neurofilament (SMI32, SMI31), myelin 233 
basic protein (SMI94), calbindin, nestin (Table 2). Additional immunohistochemistry using 234 
anti-RhoA was performed manually using pretreatment and incubation procedures described 235 
in Table 2, and breast carcinoma tissue was used as positive control (Ma et al., 2010). Negative 236 
controls where primary antibodies were omitted showed no specific labelling. A number of 237 
commercially-available antibodies against RhoA, RhoB and Cdc42 (Santa Cruz 238 
Biotechnology, Germany), RhoC and pan-Rac1 (Cell Signalling Biotechnology, UK) were also 239 
tested using formalin-fixed, paraffin-embedded human brain tissue, but no specific 240 
immunolabelling was obtained after applying a number of different antigen retrieval methods. 241 
These antibodies were excluded from further immunohistochemical studies.  242 
 243 
In situ hybridisation 244 
5µm-thick formalin-fixed, paraffin-embedded sections from selected surgical cases were 245 
processed for in situ hybridisation following supplier’s instructions (Wang et al., 2012). Probes 246 
against human RHOA, RAC1, CDC42 and RELN mRNAs were used in conjunction with ready-247 
to-use reagents from RNAscope® 2.5 HD Reagent Brown and Duplex kits (Table 2; Bio-248 
Techne, Abingdon, UK). Positive probe control, UBC, and negative probe control, dapB 249 
transcripts, were performed on Hela cell tissue (positive tissue control) and formalin-fixed, 250 
paraffin-embedded surgical human brain tissue to ensure specificity of labelling prior to final 251 
studies. Labelled sections were counterstained with Gills I haematoxylin solution (VWR, UK) 252 
before coverslipped. 253 
 254 
Image analysis 255 
Labelled sections were assessed qualitatively using a brightfield microscope (Nikon Eclipse 256 
80i), and subsequently scanned at 40x magnification using the whole slide scanner, 257 
AxioScan.Z1 (Zeiss, Germany) to obtain high-quality digital images for quantitative analysis 258 
and data interpretation. All images were viewed and analysed using the image analysis 259 
software, QuPath (Bankhead et al., 2017). Criteria for GCD: At presently, there are no strict 260 
criteria to evaluate GCD, or to identify the boundaries amongst granule cell layer and inner and 261 
outer molecular layers. In this study, the extent of GCD in each case was assessed by measuring 262 
the thickness of the granule cell layer along the external and internal limbs on haematoxylin 263 
and eosin stained, whole-slide images at 2.8x magnification. The curved region joining the 264 
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internal and external limbs of GCL was not included. An average of 19 ± 2 measurements 265 
(mean ± s.e.m.) with a mean interval of 400 ± 3 μm were made along the entire length of GCL 266 
in each case. Each line measurement was taken from the basal granule cell layer closest to CA4 267 
to the furthest dispersed DGCs in the outer molecular layer. The length of each line was then 268 
divided into three groups: ≤120 µm (no GCD, DGCs within granule cell layer as previously 269 
reported in (Blümcke et al., 2009)), between 121 to 215 µm (moderate GCD, scattered DGCs 270 
in the inner molecular layer) and ≥216 µm (severe GCD, scattered, clusters or rows of DGCs 271 
in the outer molecular layer). The threshold of 215 µm was taken from the longest line 272 
measurement to the most dispersed cell minus 120 µm (granule cell layer) to get the thickness 273 
of the molecular layer and then divided by two to derive a mid-point to divide the inner and 274 
outer molecular layer (Supplementary Material 1). The frequency of lines in each measurement 275 
group was used to categorise the extent of GCD in each case.  276 
 277 
Automated quantification of RhoA immunopositive labelling, and RhoA and Rac1-positive 278 
puncta from in situ hybridisation studies were performed using QuPath. First, granule cell 279 
layer, inner and outer molecular layers spanning 120, 215 and 310 µm from the basal granule 280 
cell layer were annotated. The software was then trained to recognise haematoxylin-stained 281 
nuclei, positive labelled cells and puncta using positive cell and subcellular detection modules 282 
(Bankhead et al., 2017). The number of cells with RhoA-positive labelling and RhoA/ Rac1-283 
positive puncta per µm², and the percentage of cells detected with RhoA immunolabelling and 284 
RhoA/ Rac1-positive puncta were recorded and compared between MTLE cases with or 285 
without GCD, three dentate regions and younger or older cohorts using non-parametric Mann-286 
Whiney or Krusal-Wallis tests in SPSS (IBM, USA; P<0.05). Spearman correlations were 287 
performed to examine the relationship between quantitative measures and thickness of granule 288 
cell layer, age of onset or age at surgery (P<0.01).  289 
 290 
Results 291 
Granule cell pathology observed in cases submitted for proteomics 292 
In MTLE cases with GCD, a thick band of NeuN-positive cells was observed in the dentate 293 
granule cell layer (Figure 1A). Two morphologies of NeuN-positive DGCs were noted: the 294 
basal population of DGCs located closer to CA4 were round and tightly packed with 295 
neighbouring DGCs (basal DGCs), and a dispersed population of NeuN-positive DGCs with 296 
round or elongated soma with uni- or bipolar processes located in outer-granular and molecular 297 
layers of the hippocampus (dispersed DGCs). In case E6, bilamination of granule cell layer 298 
was observed, and a gap of approximately 130 µm measured from bottom of the basal layer to 299 
the top of the dispersed layer was noted. No marked difference in NeuN-positive 300 
immunolabelling was noted between younger and older cohorts. In contrast, the granule cell 301 
layer in the hippocampus of four MTLE cases with no GCD (Figure 1F) and healthy post 302 
mortem controls contained round, tightly packed NeuN-positive cells, and no immunopositive 303 
cells were observed in the molecular layer.  Quantitative measures of granule cell layer revealed 304 
a significantly thicker granule cell layer in MTLE cases with GCD than cases without GCD or 305 
healthy controls (P=0.004; mean±s.e.m., range; cases with GCD 133±11 µm, 71-213 µm; cases 306 
without GCD 64±10µm, 34-82 µm; healthy controls; 70±4 µm, 63-76 µm). 307 
 308 
MAP2-positive cells were observed in the granule cell layer of all MTLE cases (Figure 1B, 309 
1G). Numerous MAP2-positive processes were observed in the granule and molecular layer. 310 
Random short MAP2-positive processes were observed in the CA4 around a few large densely-311 
labelled MAP2-positive cells. Calbindin-positive cells were observed in DGCs scattered 312 
throughout the outer-granule cell layer and molecular layer of MTLE cases with GCD (Figure 313 
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1C). In cases with GCD, calbindin-positive dispersed DGCs had round cell bodies, and 314 
occasionally, calbindin-positive cells with long processes extending into the molecular layer 315 
were noted. Not all DGCs in the outer-granular layer were calbindin-positive, and majority of 316 
basal DGCs in the sclerotic hippocampus were devoid of calbindin immunolabelling. In 317 
contrast, calbindin-positive DGCs were often observed in the granule cell layer of cases 318 
without GCD (Figure 1H). ZnT3-positive processes were observed in between DGCs in 319 
granule cell layer and in the molecular layer and CA4 subfield of cases with GCD (Figure 1D). 320 
In cases without GCD, ZnT3 immunolabelling was primarily observed in CA4 (Figure 1I). 321 
GFAP immunolabelling was observed throughout the hippocampus of all cases, with more 322 
intense labelling detected in MTLE cases with GCD (Figure 1E) compared to cases without 323 
hippocampal sclerosis or GCD (Figure 1J), and healthy controls. DGCs in granule cell layer 324 
were not immunopositive for GFAP, but GFAP-positive processes extended between DGCs in 325 
the granule cell layer, and individual GFAP-positive cells were observed in molecular layer of 326 
cases with GCD. In cases with GCD, very dense matrix of GFAP processes were observed in 327 
the CA4. In contrast, distinctive GFAP-positive cells were seen in the CA4 of cases without 328 
GCD (Figure 1J) and in healthy postmortem controls.   329 
 330 
Proteomic analysis 331 
1882 proteins were identified in the proteomic analysis of eight patients with HS Type 1 and 332 
GCD (Table 1, E1-8). 29% of the extracted proteins were observed in the basal samples only, 333 
17% in the dispersed samples only, and 54% of the proteins were observed in both samples 334 
(Figure 2B). 19% of identifiable proteins were observed in the younger cohort only, 28% in 335 
older samples only and the remaining proteins were found in both younger and older samples. 336 
Similar changes in protein expression were observed between two cases in the younger cohort 337 
(E1 and E2), and amongst three older cases, E5, E6, E8 based on hierarchical clustering (Figure 338 
2C).  339 
 340 
Common neuronal markers such as MAP2, calbindin, and calretinin were detected (Figure 2D).  341 
The protein abundance of MAP2, calretinin and calbindin were significantly higher in 342 
dispersed and younger samples than basal and older samples. The quantity of MAP2 detected 343 
was higher than calbindin and calretinin in all samples as expected based on earlier 344 
immunohistochemical studies (Figure 1B-C). Astroglial (GFAP, vimentin, S100-B) and 345 
oligodendroglial markers (Myelin Basic Protein, MBP) were also detected in all samples, 346 
consistent with immunohistochemical findings (Figure 1E). The expression of GFAP was 347 
comparable between basal and dispersed samples and was slightly higher in younger than older 348 
samples; of interest, the expression of vimentin, expressed in immature astrocytes, was 349 
predominantly observed in basal and younger samples (Figure 2D) in keeping with our 350 
previous studies (Liu et al., 2018). The expression of connexion 43, a gap junction protein 351 
expressed in astrocytes, was similar to the expression of GFAP. Common microglial-specific 352 
proteins including TREM2, LST1, HLA-DRA, SP11, MMP9 were not found in our samples, 353 
but complement component 1q subcomponent binding protein (C1QBP), a protein found to be 354 
highly expressed in microglia around site of lesion in a recent animal study (Barna et al., 2019), 355 
was found to be expressed in both dispersed and basal samples. We did not detect common 356 
markers of neural progenitors or neuroblasts including SOX2, PAX6, TBR1, TBR2, and DCX; 357 
however, a higher abundance of cell adhesion molecule 2 (CADM2), a synapse-associated 358 
protein found in subventricular neurogenic niche (Lee et al., 2012; Frese et al., 2017), as well 359 
as a number of cell cycle markers (MCM2, PCNA, Cyclin B3) were found in higher amount in 360 
the basal DGCs than dispersed DGCs in cases with GCD (Figure 2D). Neural cell adhesion 361 
molecule 1 (NCAM) was also detected in dispersed samples of cases with GCD. Together these 362 
findings suggest that apart from DGCs and astroglial cell types, minimal level of microglia and 363 
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neural progenitor cells were included in our capture. A number of proteins involved in actin 364 
and cytoskeleton remodelling including profilin-1 and 2, alpha synuclein, f-actin capping 365 
proteins, dihydropyrimidinase-related protein 2 (also known as CRMP2), and synapse proteins 366 
such as synaptotagmin-1 and synapsin-2, were identified in dispersed and younger samples at 367 
a higher level than in basal and older samples. The detection of serum albumin, carbonic 368 
anhydrase 1 and haemoglobin subunits was noted in all samples, possibly due to increased 369 
permeability of blood brain barrier in the hippocampus of patients with MTLE.  370 
 371 
Volcano plots in Figure 2E and 2H highlighted the most significantly differentially-expressed 372 
proteins between dispersed and basal samples, and between younger and older cohorts 373 
respectively. Proteins uniquely expressed in dispersed samples, and proteins significantly 374 
displaying over 1.5-fold change in dispersed compared to basal samples (Figure 2E; 375 
Supplementary Material 2) were first submitted to gene ontology and pathway bioinformatics 376 
analyses (Dispersed cluster, 330 proteins). The top functional annotation clustering based on 377 
Gene Ontology, Uniprot keywords and sequences and INTERPRO terms were GTP-binding 378 
and activity (enrichment score, 10; P=3.67x10-8), cell to cell adhesion (enrichment score, 7; 379 
P=2.61x10-6), and small GTPase-mediated signal transduction (enrichment score, 7; 380 
P=5.60x10-4); Figure 2F and Supplementary Material 3). Under the functional clustering of 381 
small GTPase-mediated signal transduction, a number of proteins in the Ras homolog (Rho) 382 
GTPase family such as RhoA, Rac1, Cdc42 and ARGAP1 and ARGAP35 were identified 383 
(Table 3 and Supplementary Material 5). Key pathways associated with differential proteins in 384 
the Dispersed cluster were related to cellular migration and actin cytoskeletal remodelling, 385 
including signalling by Rho GTPases pathway (R-HSA194315; P=1.02x10-6), axon guidance 386 
(R-HSA422475; P=1.25x10-6), regulation of actin cytoskeleton (K-HSA04810; P=1.01x10-4), 387 
and vesicle mediated transport (R-HSA5653656, P=9.29x10-7; Figure 2I and Supplementary 388 
Material 4). Rho GTPases are small GTPases that regulate cytoskeletal dynamics and cell 389 
migration, maybe of relevance to abnormal migration of DGCs in GCD. The signalling by Rho 390 
GTPases pathway shared common proteins with other pathways related to cytoskeletal 391 
dynamics as illustrated in Figure 2I. Proteins detected in basal samples only, and proteins that 392 
were significantly overexpressed in basal samples by at least 1.5-fold compared to dispersed 393 
samples (Figure 2E and Supplementary Material 2) were subsequently submitted to gene 394 
ontology and pathway enrichment analyses (Basal cluster; 555 proteins). The top functional 395 
annotation clustering included proteins involved in ribosomes, translation and RNA processing 396 
(enrichment score, 18; P=1.79x10-14), cell-cell adherens (enrichment score, 10; P=1.93x10-8), 397 
GTP binding (enrichment score, 9; P=4.31x10-7), ubiquitin-protein ligase activity (enrichment 398 
score, 4; P=4.926x10-2), and regulation of amino acid metabolic processes and proteasome 399 
activity (enrichment score, 3; P=2.07x10-2; Figure 2G and Supplementary Material 3). The 400 
interactions between proteins clustered under ribosomes, translation and RNA processing are 401 
shown as network map in Figure 2G. Pathways associated with Basal cluster were 402 
predominantly related to metabolism (R-HSA1430728, P=2.53x10-26), including amino acid 403 
(WP3925, P=234x10-5) and selenocysteine metabolisms (H-HSA2408557, P=1.71x10-24), and 404 
electron transport chain (WP111, P=4.73x10-3),  and ribosomes (K-HSA03010, P=5.00x10-13), 405 
translational mechanisms (R-HSA156842, P=2.90x10-24), and proteasomal degradation 406 
(WP111, P=4.73x10-3; Figure 2J and Supplementary Material 4).  407 
 408 
 409 
Immunohistochemical and in situ hybridisation using markers against Rho GTPases 410 
Bioinformatics analyses revealed a number of proteins in the signalling by Rho GTPases 411 
pathway either uniquely expressed or upregulated in dispersed samples of MTLE cases with 412 
GCD. To further investigate the expression of Rho GTPases, immunohistochemistry and in 413 
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situ hybridisation using antibodies and probes against RhoA, Rac1 and Cdc42 protein and 414 
mRNAs respectively were performed on surgical, formalin-fixed, paraffin-embedded, 415 
hippocampal tissue from cases submitted to proteomics, and additional surgical MTLE cases 416 
with or without GCD. Post mortem hippocampal tissue from three healthy donors were also 417 
included for qualitative assessment.  418 
 419 
In cases without GCD, majority of DGCs in the granule cell layer were immunonegative for 420 
RhoA (Figure 3A-A’). In contrast, cases with GCD had numerous RhoA-immunopositive 421 
DGCs in the outer-granule and molecular layer. RhoA-immunopositive DGCs in the granule 422 
cell layer generally had a large, round nucleus surrounded by a thin, perinuclear ‘ring’ of 423 
immunopositive labelling, or a ‘cone’ of localised RhoA immunolabelling at one end of the 424 
cell soma, usually facing either towards the molecular layer or CA4 region (Figure 3B-C). 425 
Occasionally, RhoA-positive cells in single chain formation near vascular structures were 426 
observed (Figure 3C-C’). Most RhoA-positive cells in the molecular layer had an elongated 427 
cell soma with protruding uni- or bipolar processes. In a case with a bilaminar granule cell 428 
layer (E6), most DGCs in the basal granule cell layer were devoid of RhoA immunolabelling 429 
(Figure 3D), while most DGCs in the second granule cell layer had distinct RhoA 430 
immunoreactivities in one or bipolar ends of the cell soma (Figure 3D’ and D’’). Quantitative 431 
studies revealed a significantly higher density of RhoA-positive cells and a higher percentage 432 
of cells expressing RhoA in the granule and molecular layer of MTLE cases with GCD than 433 
without GCD (mean±s.e.m; GCL, GCD 44±3%, no GCD 23±6%, P=0.035; IML, GCD 56±3%, 434 
no GCD 14±3%, P=0.001; OML GCD 27±5%, no GCD 10±3%, P=0.008; Figure 3E and data 435 
in Supplementary Material 6). In cases with GCD, a higher percentage of cells expressing 436 
RhoA were detected in the inner molecular cell layer than the granule cell layer and the outer 437 
molecular layer (IML-GCL, P=0.026; IML-OML, P=0.003; Figure 3E). In contrast, the 438 
percentage of RhoA-positive cells detected were not significantly different between regions in 439 
cases without GCD. No significant difference in density or percentage of cells expressing 440 
RhoA was noted between younger and older cohorts. A probable relationship was observed 441 
between the percentage of cells expressing RhoA and age of surgery (rs=0.390, P=0.014; Figure 442 
3F), and the mean thickness of granule cell layer (rs= 0.675, P<0.001; Figure 3G).  443 
 444 
In situ hybridisation studies using probes against RHOA and RAC1 mRNA sequences revealed 445 
fine nuclear and perinuclear puncta in DGCs in the granule and molecular layers of all cases 446 
(Figure 4A-D). RHOA-positive and RAC1-positive puncta were also observed in the neuropil, 447 
likely representing processes of DGC which were not visible in the sections. In cases with 448 
GCD, a high number of RHOA-positive and RAC1-positive puncta clustered at the polar ends 449 
of the DGC soma, particularly in DGCs situated in the molecular layer (Figure 4B, D). Some 450 
smaller haematoxylin-stained glial cells were associated with none or only a few number of 451 
RHOA-positive or RAC1-positive puncta. Further immunohistochemical and in situ 452 
hybridisation double-label studies showed that glutamine synthetase-labelled astrocytes did not 453 
have RHOA-positive or RAC1-positive puncta (Supplementary Material 7).  454 
 455 
Quantitative analyses showed that a higher density of cells with RAC1-positive puncta than 456 
RHOA was observed in MTLE with GCD (mean±s.e.m, RAC1 2.05x10-3±2.15x10-4 per µm2; 457 
RHOA 1.74x10-3±2.71x10-4; P=0.017), which was not observed in cases without GCD (RAC1 458 
1.72x10-3±2.27x10-4 per µm2; RHOA 1.25x10-3±1.81x10-4; P>0.05).  In all cases, a 459 
significantly higher density of cells with RHOA-positive puncta was observed in the granule 460 
cell layer than outer molecular layer (GCD, GCL 2.83x10-3±5.61x10-4 per µm2, OML 8.97x10-461 
4±1.01x10-4, P=0.004 (blue bars); no GCD, GCL 2.11x10-3±2.23x10-4 per µm2, OML 7.24x10-462 
4±6.94x10-5, P=0.004 (red bars); Figure 4E and Supplementary Material 6). A significantly 463 
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higher density of RHOA-positive puncta was observed in the granule cell layer than inner 464 
molecular layer in cases without GCD (GCL 2.11x10-3±2.23x10-4 per µm2, IML 9.25x10-465 
4±9.15x10-5, P=0.023), but not in cases with GCD (GCL 2.83x10-3±5.61x10-4 per µm2, IML 466 
1.49x10-3±1.84x10-4, P>0.05), indicating that the level of RHOA gene expression was more 467 
similar between granule and inner molecular layers in cases with GCD than in cases without 468 
GCD. A significantly higher density of RHOA-positive puncta was observed in the inner 469 
molecular layer of cases with GCD than without GCD (GCL 1.49x10-3±1.84x10-4 per µm2 470 
IML; no GCD IML 9.25x10-4±9.15x10-5, P=0.05). In all cases, the densities of cells with 471 
RAC1-positive puncta were higher in granule cell layer than the outer molecular layer (GCD, 472 
3.31x10-3±4.47x10-4 per µm2 GCL, 1.14x103±1.24x10-4 OML, P=0.017; no GCD, 2.92x10-473 
3±3.47x10-4 per µm2 GCL, 1.01x10-4±8.99x10-5 OML, P=0.018, Figure 4G). A significantly 474 
higher density of RAC1-positive puncta was noted in the granule cell later compared to inner 475 
molecular layer in cases without GCD (GCL 2.92x10-3±3.47x10-4 per µm2, IML 1.23x10-476 
3±1.62x10-4, P=0.001), but not in cases with GCD (GCL 3.31x10-3±4.47x10-4 per µm2, IML 477 
1.70x10-3±2.06x10-4, P>0.05). The percentage of cells with RHOA-positive and RAC1-positive 478 
puncta weakly correlate with age of onset (RHOA, rs=0.439, P=0.011, Figure 4F; RAC1, 479 
rs=0.294, p=0.049, Figure 4H). 480 
 481 
In situ hybridisation using probes against CDC42 and RELN mRNAs were also performed on 482 
surgical cases, and labelling was qualitatively assessed as only four cases were investigated. 483 
The regional distribution and density of cells with CDC42-positive puncta were similar to 484 
RHOA-positive and RAC1-positive positive labelling. RELN-positive puncta were not observed 485 
in any of these cases.  486 
 487 
Discussion 488 
We investigated the proteome of basal and dispersed DGCs in the dentate gyrus of 489 
pharmacoresistant MTLE patients with hippocampal sclerosis to explore the 490 
neurodevelopmental pathomechanisms of GCD. We have identified differences in the 491 
proteomes between basal and dispersed populations of DGCs in the hippocampus of patients 492 
with MTLE and GCD. Specifically, dispersed DGCs in cases with GCD highly expressed 493 
mature neuronal markers, MAP2, calbindin and calretinin as well as a number of Rho GTPases 494 
and proteins associated with cell migration, cytoskeleton and synapse remodelling. These 495 
results were further supported by findings from immunohistochemical and in situ hybridisation 496 
studies, where a significantly higher density and percentage of cells expressing RhoA mRNA 497 
and protein was observed in dentate gyrus of cases with GCD than cases without GCD. The 498 
expression of RhoA protein was localised to the opposite ends of uni- or bipolar of DGCs in 499 
molecular layer of cases with GCD. Consistently, the mRNAs of RHOA, RAC1 and CDC42 500 
were also found in the same intracellular region of DGCs, while RAC1 mRNA was also 501 
detected in the proximal portion of processes. These findings provide evidence supportive of 502 
DGCs undergoing neurodevelopment processes relating to cellular migration, which may 503 
contribute to the abnormal dispersion of DGCs in patients with MTLE.  504 
 505 
Comparison with previous human proteomics studies 506 
The current study reported on 1882 proteins identified from the dentate gyrus of eight patients 507 
with refractory MTLE and HS Type I and GCD (or Type II granule cell pathology according 508 
to (Blümcke et al., 2009)) using protocols established in our previous proteomic study (Liu et 509 
al., 2016). There is no specific marker for dentate granule cells in the human brain (unlike 510 
Prox1 or NeuroD in rat brains), but other neuronal markers such as MAP2 and calbindin, which 511 
are expressed by granule cells, were detected at high levels in our immunohistochemical and 512 
proteomic studies. Our samples did not capture microglial cell contaminants, but astroglial 513 
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markers (GFAP, S100-B) and myelin basic protein were detected, and this is consistent with 514 
the intimate intermingling of radial glial and myelinated axons in the dentate gyrus in MTLE 515 
with hippocampal sclerosis.  516 
 517 
Our proteomic studies did not include surgical or post mortem healthy controls as seen in most 518 
previous human proteomic studies of MTLE. This is because (i) surgically-resected ‘normal’ 519 
hippocampal tissue from healthy individuals is not available for research, (ii) the process of 520 
protein extraction for proteomic analyses is different for surgical and post mortem brain tissue 521 
so one standardised protocol cannot be applied to both type of tissue, and (iii) autopsy tissue is 522 
likely to be affected by post mortem processes such as rapid protein degradation (especially for 523 
tubulins, intermediate filaments, high motility group box protein-1, proapolioprotein, 524 
haemoglobin and mutant derivative (He et al., 2006)) which may influence our findings. In 525 
view of these arguments, we compared the protein profile of basal and dispersed DGCs as well 526 
as between younger (<35 years) and older groups (>50 years) to avoid detection of changes 527 
associated with tissue type.  528 
 529 
The differential expression of certain proteins in our study is generally consistent with findings 530 
from previous human MTLE studies. There is good agreement amongst human TLE 531 
proteomics studies that most proteins related to metabolism are significantly upregulated in 532 
epilepsy compared to archival normal brain hippocampal samples (Eun et al., 2004; Yang et 533 
al., 2006; Persike et al., 2012; Persike et al., 2018). This may be because the generation of 534 
epileptiform activity, or response to such activity, consumes a large amount of energy, and 535 
rapid glycolysis and oxidative phosphorylation are necessary to fulfil energy demands in the 536 
epileptic human brain (Kovac et al., 2017). Consistently, we found 15% of proteins extracted 537 
from our epilepsy samples were involved in metabolic processes, and up to 8% of proteins in 538 
the Basal cluster were involved in tricyclic acid cycle and mitochondrial electron chain (Figure 539 
2G and Supplementary Material 4).  540 
 541 
A key finding in this study is the identification of proteins in dispersed DGCs of cases with 542 
GCD specifically involved in axonal guidance (including beta-spectrin, growth associated 543 
protein 43, postsynaptic density protein 95, profilins), regulation of actin cytoskeleton 544 
(cytoplasmic FMR1-interacting proteins, WAVE complex proteins), cytoskeletal and synaptic 545 
remodelling (DPYL2, alpha-synuclein, synatotagmin 1, synapsin II, and stathmin1), as well as 546 
Rho GTPases signalling (RhoA, Cdc42, Rac1, brain-specific angiogenesis inhibitor, Rho 547 
GTPases activating proteins; Table 3). These processes are active during neurodevelopment 548 
and in neurogenic niches in the adult mammalian brain (Lee et al., 2012; Frese et al., 2017). 549 
Our findings are consistent with previous human proteomic studies which have reported 550 
increased expression of DPYL2 (also known as collapsing response mediator protein 2, 551 
CRMP2), a cytoplasmic phosphoprotein that binds microtubules and promotes neurite 552 
outgrowth during neurogenesis and neuronal migration (Inagaki et al., 2001; Fukata et al., 553 
2002), in the hippocampus of MTLE patients compared to controls (Persike et al., 2012; Keren-554 
Aviram et al., 2018; Persike et al., 2018). The CRMP2 antagonist, lacosamide, is an 555 
antiepileptic drug often used  in patients with drug-resistant epilepsy (Kelemen et al., 2010).  556 
 557 
GCD and neurogenesis: evidence? 558 
During neurodevelopment, new DGCs migrate from the dentate ventricular zone to the granule 559 
cell layer to form an ‘outside-in’ dentate gyrus, where the outer-granular cells are the oldest 560 
(and showing earliest NeuN immunoreactivity), and DGCs located in the inner layer (basal 561 
granule cells) are the youngest (Altman et al., 1990; Seress et al., 2001). A secondary dentate 562 
matrix is formed at gestation week (GW) 10-11 which will later become the subgranular zone 563 
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that supports ongoing neurogenesis that continues to adulthood so there is also an outside-in 564 
gradient for neurogenesis (Cipriani et al., 2017). Previous studies have reported that the dentate 565 
neurogenesis is still active postnatally at one year of age, but proliferative and neurogenic 566 
activities decline sharply between 7 to 13 years, and argued to be minimally detected in 567 
adulthood (Sorrells et al., 2018) even in the brains of adult patients with MTLE (Blümcke et 568 
al., 2001; Cipriani et al., 2017). The level of hippocampal neurogenesis in the normal and 569 
diseased adult human brain is still controversial because the detection of neural progenitor cells 570 
and new neurons in adult human brains depends on tissue quality and the immunohistochemical 571 
protocols employed in studies (Sorrells et al., 2018; Moreno-Jiménez et al., 2019). Considering 572 
that the level of neurogenesis is lower in adults than children, it is more plausible that new 573 
DGCs born in early childhood contributes to GCD. Although, our current findings did not 574 
capture immature neural progenitor cell proteins (SOX1, SOX2, TBR1, TBR2, PAX6), or 575 
neuroblast proteins (DCX), even in the youngest MTLE patients with age at surgery of twenty 576 
and twenty-two years, we did detect a number of proliferative cell cycle proteins, mini 577 
chromosome maintenance protein 2 (MCM2), proliferative cell nuclear antigen (PCNA) and 578 
cyclin B3, and immature glial progenitor protein, vimentin, in the basal DGCs of younger 579 
MTLE cases and not in the dispersed DGCs, thus providing some supporting evidence of 580 
neuroplasticity. Our previous immunohistochemical study found a number of proliferative cells 581 
expressing MCM2 in the granule cell layer of patients with MTLE (Thom et al., 2005). In 582 
addition, we detected a high abundance of neural cell adhesion molecule 1 in dispersed DGCs 583 
of younger MTLE cases. In adult animal neurogenesis studies, calretinin is transiently 584 
expressed in newborn DGCs before calbindin (Brandt et al., 2003). Calretinin was detected in 585 
the dispersed samples of this study, however as we know marked re-organisation of calretinin 586 
neurons and networks occurs in hippocampus of patients with MTLE and hippocampal 587 
sclerosis (Thom et al., 2012), calretinin may not be a reliable marker of adult neurogenesis in 588 
this context. Calbindin D28K was only detected in dispersed DGCs in our study, which is 589 
consistent with previous studies that reported reduced expression of calbindin in basal granule 590 
cell layer of patients with MTLE (Maglóczky et al., 1997; Arellano et al., 2004; Ábrahám et 591 
al., 2009; Abrahám et al., 2011; Martinian et al., 2012).  592 
 593 
We did not detect reelin, a glycoprotein secreted by Cajal-Retzius cells to regulate the 594 
migration of DGCs during neurodevelopment, in our samples. This is confirmed in subsequent 595 
in situ hybridisation studies using a probe against RELN mRNA, where no positive labelling 596 
was observed in the hippocampus of MTLE cases with GCD. This finding is consistent with 597 
previous studies that have reported low levels of RELN mRNA in MTLE patients with 598 
hippocampal sclerosis and GCD (Haas et al., 2002; Frotscher et al., 2003; Kobow et al., 2009). 599 
In those studies, reelin was detected in the CA1, 3 and 4, and we did not sample those areas. 600 
 601 
Rho GTPases and mechanisms for migration or GCD 602 
Due to the observation of Rho GTPases in the dispersed DGCs, these proteins have become 603 
the focus of further investigation as to their role in pathomechanisms underlying GCD. 604 
 605 
A main finding in this study is the upregulation of proteins involved in the Rho GTPase 606 
signalling pathway in dispersed DGCs of patients with MTLE and GCD. Rho GTPases belong 607 
to the Rho family of GTPases, which is a subgroup of Ras family of small GTP binding protein 608 
(Heasman et al., 2008). Ras homologous member A (RhoA), ras related C3 (Rac1) and cell 609 
division cycle 42 (Cdc42) are the three most-studied Rho GTPases, and the activated form of 610 
these Rho GTPases bind with a number of effector molecules (Dia, ROCK, myosin light chain, 611 
phosphatase and kinase, WAVE, Arp2/3, PAK, LIMK, Cofilin-P, Mec-3, WASP; see 612 
Supplemental Material 5) to regulate actin polymerisation, microtubule stabilisation and 613 
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actomyosin contractility during neurodevelopment when cells undergo active morphogenesis, 614 
and participate in migratory, proliferative, and survival activities (Heasman, Ridley, 2008; 615 
Zarco et al., 2019). Data from the Human Brain Transcriptome project has reported continuous 616 
gene expression of RHOA, RAC1 and CDC42 in the human hippocampus from embryonic and 617 
early fetal periods to adulthood (4 post-conceptional weeks to 60 years of age; Supplementary 618 
Material 8) (Kang et al., 2011). Similarly, we observed a high number of DGCs expressing 619 
RHOA, RAC1 and CDC42 mRNAs in the brains of adult MTLE patients with and without 620 
GCD, with age at surgery spanning 20 to 60 years. Whether the protein expression of these 621 
Rho GTPases is continuously expressed in DGCs from development to adulthood in the normal 622 
and MTLE human brain remain to be investigated as there is currently limited information. In 623 
this study, we found significantly higher protein expression of RhoA in uni- or bipolar ends of 624 
DGCs in cases with GCD than without GCD, particularly in displaced DGCs in the outer-625 
granule and molecular layers. RhoA was absent in most DGCs located in basal granule cell 626 
layer of MTLE cases. Considering the established role of RhoA in polarised cell migration in 627 
neurogenic niches, it is plausible that RhoA has a role in the mismigration of DGCs in cases 628 
with DGCs. The distinct localisation of RhoA to the apices of dispersed DGC soma may be 629 
suggestive of proximal cytoplasmic bulging, a characteristic feature of cells undergoing 630 
saltatory migratory during neurodevelopment and in neurogenic zones of adult mammalian 631 
brains (Schaar et al., 2005; Wang et al., 2019). During saltatory migration, the centrosome of 632 
the migrating cell moves forward to form a transient swelling in the proximal leading process 633 
and then cell body and nucleus move towards the centrosome then pause and this process is 634 
repeated again. Previous in vitro morphodynamic studies have found spatiotemporal changes 635 
to the expression of RhoA in migrating cells as they undergo saltatory migration (Fritz et al., 636 
2013; Martin et al., 2016; Kaneko et al., 2017). These studies detected RhoA initially at the 637 
transient swelling of the leading proximal process where RhoA interacted with effector proteins 638 
to regulate f-actin and myosin II in the actomyosin contraction to allow cell soma to translocate 639 
forward (Solecki et al., 2009; Ota et al., 2014). As the cell moved forward then stalled, RhoA 640 
expression was reduced in the front and gradually increased at the rear of the cell to facilitate 641 
retraction of cell soma and back processes, allowing the entire cell to move forward. Thus, 642 
RhoA expression may be detected at either or both ends of the cell soma depending on the 643 
cell’s migratory state. In agreement, we observed varying numbers of DGCs with RhoA 644 
accumulation in one or both ends of the cell soma in cases with GCD. Rho GTPase-mediated 645 
cell migration is a well-coordinated process during neurodevelopment, tightly regulated by a 646 
number of guanine nucleotide exchange factors and dissociation inhibitors, and GTPase-647 
activating proteins to ensure new neurons arrive timely at a specific location (Schmidt et al., 648 
2002). Genetic knockout of Rho GTPase-activating proteins, such as Gimp, in animal studies 649 
can lead to appearance of ectopic cells  (Ota et al., 2014). In this study, Gimp was not detected 650 
in our samples, but other GTPase-activating proteins, such as ARGAP1, ARGAP35, A-kinase 651 
anchor protein 13, SLIT-ROBO Rho GTPase-activating protein 3 were detected, and further 652 
studies are needed to investigate their cellular expression and role in regulating DGC migration 653 
in MTLE.  In our study, a number of RHOA and RAC1-positive puncta was observed in the 654 
neuropils of MTLE cases. It is possible that some of these positive puncta may be transcripts 655 
localised to the processes of DGCs. Previous studies have demonstrated the protein expression 656 
of Rac1 and Rho GTPases-exchange factors at the tip of leading processes of migrating cells 657 
(Shinohara et al., 2012; Hikita et al., 2014). It is also plausible that RHOA and RAC1 mRNAs 658 
are expressed in surrounding glial cells in the granule and molecular layers, although our initial 659 
double labelling experiments did not detect RHOA and RAC1 transcripts in astroglial cells 660 




Other modes of cellular migration involving Rho GTPases include ‘frog leap’ and ‘vessel-663 
based’ migrations. Using live imaging techniques, a study reported that 50% of the adult-born 664 
new DGCs had leading process pointed tangentially in the subgranular zone of the hippocampal 665 
granule cell layer, and these cells underwent lateral migration in small clusters coupled by 666 
connexion 43 before migrating radially into the deeper granule cell layer (Wang et al., 2019). 667 
During this migratory process, the leading cells in the migratory cluster changed repeatedly 668 
(akin to leapfrog), hovering forwards and backwards as the cluster moved towards their final 669 
destination. Other animal studies have also reported that gap junctions are important for 670 
neuronal dispersion in embryonic cortex (Elias et al., 2007; Elias et al., 2010; Yu et al., 2012). 671 
In our study, expression of connexin 43 was observed in dispersed DGCs of cases with GCD 672 
and we did observe a number of dispersed DGCs in single line formation in outer-granule and 673 
molecular layers of cases with GCD, sometimes in close proximity to vascular structures. In 674 
microvessel-based migration, DGCs are postulated to migrate tangentially along blood vessels, 675 
followed by limited radial migration into the granule cell layer (Sun et al., 2015). In developing 676 
animals, it is known that large plexuses of vasculature are developed in the molecular layer and 677 
CA4 during postnatal day 0 to 7, while only short bridges of blood vessels are found to extend 678 
through the granule cell layer (Pombero et al., 2018).  679 
 680 
CONCLUSION 681 
In conclusion, we have shown limited evidence to support ongoing adult neurogenesis in the 682 
hippocampus of patients with MTLE, but evidence of differential dysmaturation between 683 
dispersed and basal DGCs has been shown. We have provided evidence from proteomic and 684 
immunohistochemical studies to demonstrate that DGCs contribute to ongoing structural and 685 
synaptic changes in the MTLE human brain, and expression of Rho GTPases in these cells may 686 
support abnormal cellular migratory activities that are linked to GCD pathology. Further 687 
studies are required to assess the possible contribution of DGCs expressing Rho GTPases to 688 
seizure generation and cognitive impairments.  689 
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interventions. The present study explored the protein profiles of granule cells situated in the 713 
basal (control) and dispersed hippocampal granule cell layer of eighteen patients with Mesial 714 
Temporal Lobe Epilepsy and granule cell pathology. Proteomics and bioinformatics analyses 715 
demonstrated that many key Rho GTPases and related proteins were upregulated in displaced 716 
granule cells, and further in situ hybridisation and immunohistochemical studies showed that 717 
mRNAs and proteins of Rho GTPases were spatially located in polar ends of cell body and 718 
proximal part of extending processes, resembling Rho GTPases expression in actively 719 
migrating cells during neurodevelopment. Findings from our study suggest that hippocampal 720 
granule cells may undergo Rho GTPase-mediated migration, possibly contributing to granule 721 
cell pathology and hippocampal reorganisation in MTLE. 722 
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Table and figure legends  735 
 736 
Table 1. Clinical details of cases studied. Eight cases with Hippocampal Sclerosis Type I 737 
(according to the International League Against Epilepsy classification system) and granule cell 738 
dispersion were analysed using proteomics (E1-8, in grey). In addition to these cases, another 739 
ten surgical cases with MTLE and three post mortem normal cases were included in RhoA and 740 
Rac1 immunohistochemical and/or in situ hybridisation studies. In situ hybridisation studies 741 
using probes against CDC42, or RELN transcripts were performed on four cases (E1P, E122, 742 
E1, E3). Abbreviations: Carb, carbamazepine; COD, cause of death, Clob clozabam; Dia 743 
diazepam, Gaba, Gabapentin; GCD, granule cell dispersion; GG ganglioglioma; HS 744 
hippocampal sclerosis; Lam, Lamotrigine; Lev, Levetiracetam; MCD malformation of cortical 745 
development; MFS mossy fibre sprouting; OH oligodendroglial hyperplasia in white matter; 746 
Ox, Oxcarbazepine; Pheny, Phenytoin; Pheno, Phenobarbitone; Preg, Pregabalin; Prim, 747 
Primidone; TS temporal sclerosis, Tem temapazem, Top topirmate; Val, Sodium valproate; 748 
Zon, Zonisamide. 749 
 750 
Table 2 Antibodies and protocols for chromogenic in situ hybridisation and 751 
immunohistochemical studies. Automated immunohistochemistry was performed using the 752 
Bond Max automated immunostainer and reagents (Leica, Milton Keynes, UK). *RNA 753 
detection was performed using RNAscope patent assays system following supplier’s 754 
instruction. Abbreviations: aa, amino acids; Cdc42 Cell division control protein 42 homolog; 755 
GFAP, glial fibrillary acidic protein; K, thousands; MAP microtubule associated protein; 756 
NeuN, neuronal nuclei; ov, overnight, Rac1 Ras-Related C3 Botulinum Toxin Substrate 1; 757 
RhoA Transforming protein RhoA or Ras homolog family member A; RT room temperature. 758 
Antigen retrieval buffers: ENZ1, Leica Bond enzyme concentrate and diluent; ER1, Leica 759 
Bond citrate-based buffer; ER2, Leica Bond EDTA-based buffer; H-3301, Vector’s Tris-based 760 
buffer pH 9.0; H-3300, Vector’s citrate-based buffer pH 6.0; SC, Sodium citrate buffer, pH 761 
6.0. Suppliers: Abcam plc., Cambridge, UK; BD Transduction Lab., Oxford, UK; Bio-Techne, 762 
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Abingdon, UK; DAKO, Cambridgeshire, UK; Millipore, Watford, UK; Sternberger, Maryland, 763 
US; Swant, Marly, Switzerland; Thermo Fisher Scientific, Hemel Hempstead, UK; Synaptic 764 
systems, Goettingen, Germany. 765 
 766 
Figure 1 Hippocampal pathology observed in a MTLE patient with Hippocampal 767 
Sclerosis and Granule Cell Dispersion. (A) NeuN-positive granule cells were observed in the 768 
granule cell layer of the hippocampal dentate gyrus. The number of dentate granule cells 769 
(DGCs) remained abundant despite marked loss of pyramidal neurons in the cornu Ammonis 770 
(CA) 1, 3 and 4 subfields, which are typical features of Hippocampal Sclerosis Type 1 based 771 
on classification scheme established by the taskforce of International League against Epilepsy 772 
(ILAE)(Blumcke et al., 2013). However, majority of the NeuN-positive DGCs appeared to 773 
scatter in rows or clusters to the outer-granular layer and molecular layer (MOL), which is 774 
consistent with granule cell dispersion pathology. NeuN-positive pyramidal neurons were still 775 
observed in the CA2 region. (B) Strong MAP2-positive DGCs were observed in the granule 776 
cell layer. MAP2-positive DGCs had immunopositive fibres projected towards the molecular 777 
layer, and MAP2-positive labelling appeared to be stronger in the molecular layer than in the 778 
basal granule cell layer. MAP2-positive fibres of various length and a small number of MAP2-779 
positive cells were observed in CA4 region. (C) Calbindin immunoreactivity was observed in 780 
most, but not all, dispersed and elongated DGCs in the granule and molecular layer. In contrast, 781 
small, round basal DGCs were immunonegative for calbindin. An intense blush of granular 782 
calbindin-positive labelling was also observed in the molecular layer. (D) Intense ZnT3-783 
positive labelling was observed in the molecular layer, particularly in the inner molecular layer. 784 
This is consistent with mossy fibre sprouting pathology in MTLE. Clusters of ZnT3-positive 785 
fibres were observed predominantly in the CA4 region.  (E) Dense matrix of GFAP-positive 786 
fibres was observed in all CA regions. GFAP-positive radially-directed fibres extended 787 
between DGCs in the granule cell layer, and GFAP-positive cells were visible in the molecular 788 
layer. (F-J) Images showing the immunoreactivities of NeuN, MAP2, calbindin, ZnT3 and 789 
GFAP in the hippocampus of a MTLE patient with no remarkable hippocampal pathologies. 790 
Scale bars in A left 500 µm, and A right 50 µm. 791 
 792 
Figure 2 Bioinformatics analyses. (A) An image of a toluidine-stained hippocampal tissue 793 
section showing marked granule cell dispersion pathology (top). DGCs were extracted from 794 
frozen hippocampal tissue sections during laser microdissection. Extracted DGCs (including 795 
nuclei and ~10µm-perinuclear rim as cytoplasm) were divided into either basal or dispersed 796 
samples per case based on their location within the dentate gyrus. Basal samples contained 797 
DGCs located in the basal layer of the granule cell layer (black outline). These round DGCs 798 
were closely situated to neighbouring DGCs, and they were aligned along the border of CA4 799 
and granule cell layer. Dispersed samples contained mixture of round and elongated DGCs 800 
located ectopically, in rows or clusters in the outer-granular, inner and outer molecular layers 801 
(green outline). Individual, small, round nuclei scattered in the dentate gyrus, sometimes in 802 
close proximity to DGCs, were likely to glial cells, and therefore these small cells were avoided 803 
where possible. (B) 1882 proteins were identified from proteomic analyses of basal and 804 
dispersed DGCs of eight cases with MTLE, hippocampal sclerosis and GCD. More than 50% 805 
of the identifiable proteins were shared between basal and dispersed samples, and between 806 
younger (<35 years) and older cohorts (<50 years). Less than one-third of the identifiable 807 
proteins were uniquely detected in basal, dispersed, younger and older samples. (C) A 808 
dendrogram showing hierarchical clustering of all differentially expressed proteins in eight 809 
MTLE cases with GCD. The pattern of protein changes between dispersed and basal samples 810 
was more similar between cases E1 and E2 (younger cohort) and E5, E6 and E8 (older cohort). 811 
(D) Heat map showing logarithmic-2 fold change between dispersed and basal samples (D/B), 812 
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or younger or older cohorts (Y/O) of selected proteins expressed in neuronal (MAP2, calbindin, 813 
calretinin), glial (GFAP, S100-B, MBP, connexion 43), vascular (VEGFR), immature cell 814 
(vimentin) and proliferative populations (MCM2, MCM4, PCNA, cyclin B3), or are proteins 815 
associated with cytoskeletal (profiling-1, alpha synuclein, f-actin capping protein, DPYL2, 816 
stathmin) and synapse remodelling (synaptotagmin-1, synapsin-2), mTOR pathway (PS6, PS6 817 
kinase), neurogenic niches (NCAM1, CADM2), vascular changes (carbonic anhydrase 1, 818 
haemoglobin) and inflammation (C1QBP, HSP70). Keys: * or ^ significantly overexpressed 819 
proteins (P<0.05), **proteins found in dispersed samples of GCD cases only, ***proteins 820 
found in basal samples of GCD cases only, ^^proteins only found in younger cohort only, 821 
^^^proteins found in older cohort only. Abbreviations: C1QBP, complement component 1Q 822 
subcomponent-binding protein; DPYL2, dihydropyrimidinase-related protein 2; GFAP glial 823 
fibrillary acidic protein; HSP70, heat shock proteins; MAP2, microtubule associated protein 2; 824 
MBP myelin binding protein; MCM2, minichromosomal maintenance 2; NCAM1, neural cell 825 
adhesion molecule 1; PCNA, proliferating cell nuclear antigen; PS6 ribosomal protein S6; 826 
VEGFR vascular endothelial growth factor receptors. (E, H) Volcano plots showing 827 
logarithmic-2 fold change against –log P value for proteins that were expressed in both 828 
dispersed and basal samples (E) or in both younger and older cohorts (H). Significantly 829 
differentially expressed proteins that showed over 1.5-fold change were highlighted in the plots 830 
(P<0.05). (F, G) The abundance of each protein was compared between basal and dispersed 831 
samples, and between younger and older cohorts. Proteins that were uniquely expressed in one 832 
group only, and proteins that were significantly expressed by 1.5-fold than comparative group 833 
(fold change>1.5, P<0.05) generated the Dispersed, Basal, Younger and Older clusters. Each 834 
cluster was submitted to bioinformatics platforms for Gene Ontology and Pathways analyses. 835 
Top functional annotation clusters based on Gene Ontology, Uniprot keywords and sequences 836 
and INTERPRO terms for proteins in the Dispersed (F) and Basal clusters (G) were listed 837 
(P<0.01; also refer to Supplementary Material 3). The enrichment scores generated by 838 
bioinformatics platforms, and the percentage of proteins submitted that were associated with 839 
each functional annotation cluster are illustrated. Network maps show the connections between 840 
proteins in small GTPase mediated signal transduction (F) and ribosomes annotation clusters 841 
(G). (I, J) Proteins in the Dispersed and Basal clusters were significantly involved in a number 842 
of pathways (P<0.01; also refer to Supplementary Material 4). The size of the circle represents 843 
the number of proteins submitted that were involved in the pathways. The thickness of 844 
connections refers to the number of proteins that belongs to both connecting pathways. 845 
 846 
Figure 3 RhoA immunohistochemical studies. (A) Most DGCs were immunonegative for 847 
RhoA in the granule cell layer of a MTLE case without GCD (E5P). Occasionally, weak 848 
perinuclear RhoA-positive labelling were observed in a few DGCs (A’, higher magnification 849 
of area outlined in A). No DGCs were observed in the molecular layer of cases without GCD. 850 
(B-C) Numerous DGCs with intense RhoA immunolabelling were observed in the granule and 851 
molecular cell layer of two MTLE cases with GCD (E14, B; E3, C). In some DGCs, RhoA 852 
immunolabelling was detected in one polar end of the DGC soma directed towards the CA4 or 853 
molecular layer. A number of RhoA-positive cells in the outer-granular and molecule layer had 854 
elongated soma with uni- or bipolar processes (B’ and C’). In bipolar DGCs, RhoA 855 
immunolabelling was observed at one or both apices of cell soma. Occasionally, RhoA-positive 856 
DGCs were found to align single line formation near blood vessels (C’). In contrast, most basal 857 
DGCs closest to the CA4 border had no or minimal RhoA immunolabelling. (D) Bilamination 858 
of the granule cell layer was observed in a case with MTLE and GCD (E6). In this case, most 859 
DGCs in the basal granule cell layer appeared to be devoid of RhoA immunolabelling. In 860 
contrast, nearly all DGCs in the outer-granule layer (D’) and second granule cell layer 861 
expressed RhoA (D’’) either in one or both ends of the cell. Majority of RhoA-positive cells in 862 
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the second granule cell layer had stronger and distinct RhoA immunoreactivities in the end 863 
directed towards the molecular layer. (E) A boxplot showing that the percentage of cells with 864 
RhoA-positive labelling in the dentate gyrus of MTLE cases with GCD (blue) or without GCD 865 
(red). A significantly higher percentage of cells expressing RhoA was observed in granule and 866 
molecular layers of cases with GCD than cases without GCD (GCL, P=0.035; IML, P=0.001; 867 
OML, P=0.008; see Supplementary Material 6). In cases with GCD, the percentage of cells 868 
with RhoA immunolabelling was significantly higher in the inner molecular layer than the 869 
granule cell (P=0.026) and outer molecular layer (P=0.003). (F-G) The percentage of cells 870 
expressing RhoA in the dentate gyrus weakly correlated with the age at surgery of MTLE 871 
patients (rs=0.390, P=0.014; F) and the mean thickness of granule cell layer (rs=0.675, P<0.001; 872 
G). Abbreviations: DG dentate gyrus; GCL granule cell layer; IML, inner molecular layer; 873 
OML, outer molecular layer. Scale bars, 50 µm. 874 
 875 
Figure 4 RHOA and RAC1 in situ hybridisation studies. (A-D) RHOA and RAC1-positive 876 
puncta (cyan) were observed in the dentate gyrus (DG) of MTLE cases without GCD (A, C) 877 
and cases with GCD (B, D). Majority of positive puncta were found in or around haematoxylin-878 
stained nuclei (purple) in the granule and molecular cell layers. In MTLE cases with GCD, 879 
most RHOA and RAC1-positive puncta were localised peri-nuclearly and at opposite ends of 880 
each nucleus (B, D). Many RAC1-positive puncta were also observed in the proximal portion 881 
of uni- or bipolar processes (D). A number of RHOA and RAC1-positive puncta were also 882 
observed in the neuropils. (E, G) In cases without GCD, the density of cells with RHOA and 883 
RAC1-positive puncta was higher in the granule cell layer than inner (RHOA P=0.023; RAC1 884 
P=0.001) and outer molecular layer (RHOA P=0.004; RAC1 P=0.018). In cases with GCD, 885 
significantly higher densities of cells with RHOA and RAC1-positive puncta were observed in 886 
the granule and outer molecular layers (RHOA P=0.004; RAC1 P=0.017), but not in the inner 887 
molecular layer (P>0.05). The density of cells expressing RHOA mRNAs in the inner molecular 888 
layer was significantly higher in cases with GCD than cases without GCD (P=0.05), but this 889 
difference was not observed in granule cell layer or outer molecular layer (P>0.05).   (F, H) 890 
The percentage of cells with RHOA or RAC1-positive puncta weakly correlated with age of 891 
onset in patients with GCD (RHOA, rs=0.439, P=0.011; RAC1, rs=0.295, P=0.049), but not in 892 
patients without GCD. Abbreviations: DG dentate gyrus; GCL granule cell layer; IML, inner 893 
molecular layer; OML, outer molecular layer. Scale bars, 50 µm.  894 
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 898 
Supplementary Material 1 Schematic diagram showing basal and dispersed populations of 899 
DGCs within the dentate gyrus of MTLE cases with or without GCD. 900 
 901 
Supplementary Material 2 Proteins that were significantly overexpressed in specific clusters 902 
as illustrated in Figure 2E and 2H. 903 
 904 
Supplementary Material 3 Top eight functional annotation clusters associated with proteins in 905 
Dispersed and Basal clusters. Also refer to Figure 2F and 2G. 906 
 907 
Supplementary Material 4 Pathways associated with proteins in Dispersed and Basal clusters 908 
(P<0.01). Also refer to Figure 2I and 2J. 909 
 910 
Supplementary Material 5 Diagram illustrating the role of Rho GTPases and their effector 911 




Supplementary Material 6 Quantitative results from immunohistochemical and in situ 914 
hybridisation studies. 915 
 916 
Supplemental Material 7 Additional findings from in situ hybridisation studies. 917 
 918 
Supplemental Material 8 Transcriptome expression of RHOA, RAC1 and CDC42 in fetal and 919 
adult postmortem human brains extracted from the Human Brain Transcriptome (Kang et al., 920 
2011). 921 
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 Table 1. Clinical details of cases studied. Eight cases with Hippocampal Sclerosis Type I 1297 
(according to the International League Against Epilepsy (ILAE) classification system) and 1298 
granule cell dispersion were analysed using proteomics (E1-8, in grey). In addition to these 1299 
cases, another ten surgical cases with MTLE and three post mortem normal cases were included 1300 
in RhoA and Rac1 immunohistochemical and/or in situ hybridisation studies. In situ 1301 
hybridisation studies using probes against CDC42, or RELN transcripts were performed on four 1302 
cases (E1P, E122, E1, E3). Abbreviations: Carb, carbamazepine; COD, cause of death, Clob 1303 
clozabam; Dia diazepam, Gaba, Gabapentin; GCD, granule cell dispersion; GG ganglioglioma; 1304 
HS hippocampal sclerosis; Lam, Lamotrigine; Lev, Levetiracetam; MCD malformation of 1305 
cortical development; MFS mossy fibre sprouting; OH oligodendroglial hyperplasia in white 1306 
matter; Ox, Oxcarbazepine; Pheny, Phenytoin; Pheno, Phenobarbitone; Preg, Pregabalin; Prim, 1307 
Primidone; TS temporal sclerosis, Tem temapazem, Top topirmate; Val, Sodium valproate; 1308 

































20 to 30 
years  
E1 FS  13 
Carb, Lam, 
Lev, Mid, Val 
No remarkable 
cognitive deficits 











abilities and language 
functions  






FS  14 
Carb, Lev, Ox, 
Val 
Weak verbal and 
recognition functions 





E122 none 14 
Carb, Lam, 
Preg 
Weak working and 
verbal memory 









abilities and memory. 
Weak visuospatial 
processing abilities  





E16 None  9 
Lam, Lev  
 
Average cognition and 
memory functions 










intelligence and verbal 
and visual memory  






E12 None 15 Lam, Zon  Weak verbal memory 




31 to 40 
years 
E4  None 10 Carb, Lev 
Average cognition and 
memory functions 










8 Carb, Lev, Dia 
Weak verbal and 
working memory 
Depression. Psychosis. 





E13 FS  1 
Val, Clob, 
Carb 
Average cognition and 
memory functions.  






41 to 50 
years 
E5P None  2 Lev, Carb, Weak visual memory 




E11 None 8 
Clonazepam, 
Ox 
Weak cognition and 
and visual memory. 
Depression, Paranoia 





























Carb, Ox, Lev, 
Lam, Pheno 
Weak verbal and non-
verbal memory. 
Psychosis  





E7 n/a 11 
Val, Preg, 
Carb 
Weak verbal memory 
and spatial recognition. 
Paranoia  







E1P FS  22 Carb, Clob  
Impaired intellectual 
ability and visual and 
verbal memory 










Lam, Prim  
Poor verbal memory  
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Table 2 Table 2 Antibodies and protocols for RNA and immunohistochemical studies. 1311 
Automated immunohistochemistry was performed using the Bond Max automated 1312 
immunostainer and reagents (Leica, Milton Keynes, UK). *RNA detection was performed 1313 
using RNAscope patent assays system following supplier’s instruction. Abbreviations: aa, 1314 
amino acids; Cdc42 Cell division control protein 42 homolog; GFAP, glial fibrillary acidic 1315 
protein; K, thousands; MAP microtubule associated protein; NeuN, neuronal nuclei; ov, 1316 
overnight, Rac1 Ras-Related C3 Botulinum Toxin Substrate 1; RhoA Transforming protein 1317 
RhoA or Ras homolog family member A; RT room temperature. Antigen retrieval buffers: 1318 
ENZ1, Leica Bond enzyme concentrate and diluent; ER1, Leica Bond citrate-based buffer; 1319 
ER2, Leica Bond EDTA-based buffer; H-3301, Vector’s Tris-based buffer pH 9.0; H-3300, 1320 
Vector’s citrate-based buffer pH 6.0; SC, Sodium citrate buffer, pH 6.0. Suppliers: Abcam plc., 1321 
Cambridge, UK; BD Transduction Lab., Oxford, UK; Bio-Techne, Abingdon, UK; DAKO, 1322 
Cambridgeshire, UK; Millipore, Watford, UK; Sternberger, Maryland, US; Swant, Marly, 1323 
Switzerland; Thermo Fisher Scientific, Hemel Hempstead, UK; Synaptic systems, Goettingen, 1324 
Germany. 1325 





Immunogen or target 
epitope  










Purified cell nuclei from 
mouse brain 
Nuclei of most neurons, 
some proximal dendrites 
ER1 (20) 




Phosphorylated epitope in 
neurofilament H and M 






in neurofilament H 







Neurons H-3301 (12) 







H-3301 (12) Swant; 1:10k, ov, 4oC 
Anti-ZnT3 
197-003 
Recombinant protein of 
mouse ZnT3 (aa. 2-75) 




1:10K, ov, 4oC 
SMI 94 
SMI-94R 
70-89 aa of human myelin 
basic protein 
Myelinated fibre in white 
matter 
ENZ1 (10) 




150 aa recombinant 
fragment from human nestin 
conjugated to GST 
Immature progenitors, glia, 
endothelial cells 
H-3301 (12) 
Abcam; 1:1K, ov, 
4oC 
Anti-GFAP Z0334 
GFAP isolated from cow 
spinal cord 
Astrocytes, some ependymal 
cells 
ENZ1 (10) 




A synthetic peptide from 
human Transforming protein 
RhoA conjugated to an 
immunogenic carrier protein 
Small GTPase protein that 
regulates actin cytoskeleton 
in the formation of stress 
fibres, and cell division. 
Expresses in cytoplasm of 
cells undergoing structural 








NM_001664.2. Probe region 







NM_006908.4 Probe region 







NM_044472.2 Probe region 







NM_173054.2 Probe region 
from 4401 to 5340 
Glycoprotein expressed by 





  1327 
33 
 
Table 3: Proteins in the Dispersed cluster that were involved in signalling by Rho GTPases 1328 
pathway (Reactome, R-HSA194315; P=4.68x10-9).  1329 
 1330 
Entry ID Gene  Protein              1331 
P60953  CDC42  Cell division control protein 42 homolog    1332 
E7EVJ5 CYFIP2  Cytoplasmic FMR1-interacting protein 2    1333 
Q7L576 CYFIP1  Cytoplasmic FMR1-interacting protein 1    1334 
F8W7L3 A2M   Alpha-2-macroglobulin      1335 
Q12802 AKAP13  A-kinase anchor protein 13      1336 
H0YE29 ARHGAP1  Rho GTPase-activating protein 1    1337 
Q9NRY4 ARHGAP35  Rho GTPase-activating protein 35     1338 
I3L4C2  BAIAP2 Brain-specific angiogenesis inhibitor associated protein 2 1339 
P11274  BCR   Breakpoint cluster region protein     1340 
A0A087X0P0 CENPE  Kinesin-like protein  Dispersed  1341 
G3XAM7 CTNNA1 Catenin-alpha-1 1342 
P78352  DLG4   Disks large homolog 4       1343 
Q99880 HIST1H2BL  Histone H2B type 1-L       1344 
Q15691 MAPRE1  Microtubule-associated protein RP/EB family member 1  1345 
Q9Y2A7 NCKAP1  Nck-associated protein 1      1346 
Q9NZQ3 NCKIPSD  NCK-interacting protein with SH3 domain    1347 
P35080  PFN2   Profilin-2        1348 
P62140  PPP1CB  Serine/threonine-protein phosphatase PP1-beta catalytic  1349 
C9J9C1 PPP2R1A  Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A  1350 
P63000  RAC1   Ras-related C3 botulinum toxin substrate 1    1351 
C9JNR4 RHOA   Transforming protein RhoA/ Ras homologous family member A   1352 
P62745  RHOB   Rho-related GTP-binding protein RhoB     1353 
Q8IXI2  RHOT1  Mitochondrial Rho GTPase 1      1354 
P31947  SFN   14-3-3 protein sigma       1355 
O43295 SRGAP3  SLIT-ROBO Rho GTPase-activating protein 3    1356 
A2IDB2 YWHAH  14-3-3 protein eta   1357 
 1358 
 1359 
